-Employee volunteers design and lead many Diversity + Inclusion efforts, particularly our Employee Resource Networks.” Alexion Stance on diversity and inclusion: Information not public ERGs Information not public In select countries, third-party companies manage our local commercial operations. At Alexion, our individual uniqueness and shared humanity flourish through our relentless commitment to diversity, inclusion, and belonging.”, Of diversity, inclusion, and belonging, the latter is of paramount importance. We focus on initiatives that advance emotional well-being, provide educational opportunities for disadvantaged and disenfranchised people, and promote diversity and inclusion in society and critical institutions. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. “Uzair has been instrumental in helping to shape Alexion’s approach to diversity and inclusion to date, and I am confident that, in this new role, he will help us build a stronger, even more inclusive organization, while ensuring every voice within the company is heard.”. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of Uzair Qadeer as the company’s first Chief Diversity Officer. Employee-led learning program designed to celebrate unique voices and elevate our understanding of diversity as a powerful and immersive reflection of who we are and can be. These targeted teams are activated to tackle topics of the highest priority. Media I have gained new friends and connections just by sharing who I am.”, As a member of the Human Experience Leadership Team, Alcira helps Alexion rethink approaches to embed DI&B into our human resources processes and ways of working. This press release features multimedia. Forum for open, authentic, and courageous conversations to ignite positive change and build a culture of equity, inclusion, and opportunity. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ materially from those forward-looking statements, including for example: the Company may not be able to implement its planned DI&B initiatives, the Company may not realize the benefits from the DI&B initiatives contemplated by the Company; the Company may not be able to implement some or all of its DI&B plans; our dependence on sales from our principal product (SOLIRIS); our ability to facilitate the timely conversion from SOLIRIS to ULTOMIRIS; payer, physician and patient acceptance of ULTOMIRIS as an alternative to SOLIRIS; the impact of the COVID-19 pandemic on Alexion’s business, including its sales, clinical trials, operations, DI&B and HR initiatives, and supply chain; future competition from biosimilars and novel products; decisions of regulatory authorities regarding the adequacy of our research, marketing approval or material limitations on the marketing of our products; delays or failure of product candidates to obtain regulatory approval; delays or the inability to launch product candidates due to regulatory restrictions, anticipated expense or other reasons; results in early stage clinical trials may not be indicative of full results or results from later stage or larger clinical trials (or in broader patient populations) and do not ensure regulatory approval; the possibility that current rates of adoption of our products are not sustained; the adequacy of our pharmacovigilance and drug safety reporting processes; failure to protect and enforce our data, intellectual property and proprietary rights and the risks and uncertainties relating to intellectual property claims, lawsuits and challenges against us (including intellectual property lawsuits relating to ULTOMIRIS brought by third parties against Alexion); the risk that third party payors (including governmental agencies) will not reimburse or continue to reimburse for the use of our products at acceptable rates or at all; potential declines in sovereign credit ratings or sovereign defaults in countries where we sell our products; delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement; uncertainties surrounding legal proceedings, company investigations and government investigations; the risk that estimates regarding the number of patients with PNH, aHUS, gMG, NMOSD, HPP and LAL-D and other indications we are pursuing are inaccurate; and a variety of other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended June 30, 2020 and in our other filings with the SEC. Katie Payne, 202-669-6786 Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. “At Alexion, DI&B is on everybody’s mind nurtured by curiosity, team spirit, and a strong feeling of responsibility.”. BOSTON –(BUSINESS WIRE)–Aug. Marta joined the Global Regulatory Affairs organization at Zurich, one of Alexion’s major hubs, in 2019. “Helping WIL and DI&B at Alexion gives me great energy and joy as I feel connected and contribute to the well-being of colleagues and the community around us,” Marta shares. This website is intended only for residents of the United States. Our work isn’t done until our employees and patients can feel a true sense of belonging,” said Mr. Qadeer. Diversity, Inclusion, and Belonging Communications Lead at Alexion Pharmaceuticals, Inc. Baltimore, Maryland 500+ connections. Alcira’s storyOriginally from Mexico, Alcira immigrated to the United States for college. The company joins … Advising body charged with providing guidance and championing DI&B solutions across the organization, co-chaired by executive committee members, and composed of a diverse group of cross-functional and cross-geographical employees. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Chris Stevo, 857-338-9309 In addition to her day job, Marta helped launch and is currently leading the Zurich Chapter for Women in Leadership (WIL), Alexion’s employee resource group. Leading a team of exceptional professionals across multiple geographic regions is a firsthand responsibility when it comes to diversity, inclusion, and belonging (DI&B). This alliance is comprised of ~10% of Alexion’s global workforce and mobilizes enterprise-wide DI&B agents to innovate, pilot, and amplify new and novel DI&B solutions at an accelerated pace through the democratization of employee ideas and voices. Alexion joins a majority of Big Pharma with C-level execs focused on diversity, particularly relevant in the cu Our bold mission does not stop with diversity and inclusion. They create communities and advocacy, raise cultural awareness, represent Alexion at external events, and drive business impact by harnessing diverse perspectives. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of Uzair Qadeer as the company’s first Chief Diversity Officer. “Magnetizing and incubating diverse talent will allow us to harness diverse insights that fuel innovation and create value for the patients we serve. “After sharing my story and the importance of Dia de Muertos in Mexican culture, colleagues reached out to thank me and learn more. -Our Global Diversity + Inclusion team within Human Resources offers strategic and day-to-day direction on implementation. Prior to assuming the role of Chief Diversity Officer, Mr. Qadeer served as Vice President, Head of Enterprise Partnership at Alexion, helping the company build leading-edge vision and capabilities in executive coaching, HR business partnership, and strategic workforce planning, while shaping the company’s initial DI&B strategy. Alexion Pharmaceuticals named its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion. In fact, she explains, “It was clear to me that Alexion will give me an opportunity to be who I am while being surrounded by highly talented and diverse colleagues making a difference in patients’ lives.”. Before joining Alexion in February 2019, Mr. Qadeer worked in roles of increasing responsibility in Deloitte’s Human Capital consulting practice where he advised clients across industries and geographies on forward-looking human capital topics spanning talent management, organizational design and development, human resources management, and diversity, equity and inclusion. I am committed to activating this purposeful vision.”. Diversity, Inclusion & Belonging Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. About Uzair. Apply to Diversity and Inclusion Manager, Freelance Writer, Executive Assistant and more! She has also shared her own story as part of a global listening and learning program celebrating Hispanic and Latinx cultures. Prior to that, Mr. Qadeer worked at Bristol Myers Squibb Company, expatriating to Rome, Italy and gaining deep insights in global and international work. Alexion encourages diversity of backgrounds and ideas. We strive to foster a true sense of belonging. Diversity & Inclusion ... Glassdoor has 501 Alexion Pharmaceuticals reviews submitted anonymously by Alexion Pharmaceuticals employees. That is why we have a governance structure that actively engages our global workforce spanning every level, function, and geography to shape, champion, and activate our efforts. Inclusion is having a voice at the table. Our mission is to ignite an inclusive environment where people belong because of their uniqueness and unleash their individuality and diversity to spur innovative breakthroughs for patients. It is critical for every person to belong because of their uniqueness, not despite it. Our commitment to gender and ethnic diversity extends to all ranks within our organization. Forward-Looking Statement Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion. Mr. Qadeer received his master’s degree as well as his B.A. When Albie was born, his mom, Charlotte, said that he was “absolutely fine. Forum for focusing on commonalities, not differences, to encourage dynamic conversations about the experiences among people with different overlapping identities. • Created and executed a culture transformation vision and diversity/inclusion strategy aligned to the Business strategy. By using our website, you agree to our use of cookies in accordance with our, Alexion Announces Appointment of First Chief Diversity Officer. Systemic change can only come by way of individual change. BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of Uzair Qadeer as the company’s first Chief Diversity Officer. We genuinely care for and respect each other, working together as a high-performing team to deliver extraordinary results while embracing different perspectives. “We are a highly committed team delivering much needed medicines for patients in rare disease across many countries in Europe, Latin America, Canada, Switzerland, United Kingdom, Ireland to Australia,” Marta describes. As an HR futurist, he is focused on rethinking DE&I. ... Chief Diversity Officer at Alexion Pharmaceuticals, Inc. Alcira vividly remembers her Alexion interview—the people she met made her feel like she authentically belonged. “Now that I have been with Alexion for over a year, I’m still amazed by the organization’s commitment to diversity, inclusion, and belonging (DI&B).” As a DI&B champion and advocate, Alcira has attended powerful colleague conversations focused on diversity and inclusion. As a father of two young children, Donnan recalls being afraid of what the future would hold prior to his diagnosis. BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (ALXN) today announced the appointment of Uzair Qadeer as the company’s first Chief Diversity Officer. The third key shift happening in HR, according to Qadeer, is the shift from diversity to belonging. Make a difference for families like Tristan's. Jacobs, a former chief diversity officer at investment management firm Eaton Vance, will be "responsible for further developing JLL's global diversity and inclusion … The Securities and Exchange Commission today announced that Boston-based pharmaceutical company Alexion Pharmaceuticals Inc. has agreed to pay more than $21 million to resolve charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act (FCPA). Since then, she has discovered her passion of surrounding herself with a diverse set of friends and colleagues. At Alexion, DI&B is on everybody’s mind nurtured by curiosity, team spirit, and a strong feeling of responsibility.”, “At Alexion, DI&B is on everybody’s mind nurtured by curiosity, team spirit, and a strong feeling of responsibility.”. Alexion offers promise and cultivates a sense of belonging as we positively impact our local communities. I have gained new friends and connections just by sharing who I am.”, “After sharing my story and the importance of Dia de Muertos in Mexican culture, colleagues reached out to thank me and learn more. We strive to create an environment that enables individuals to thrive in their sense of long-term belonging. Married with a newborn son, Ruthie was scared to learn that PNH was a life-threatening illness that at the time had no approved treatment. After sharing my story and the importance of Dia de Muertos in Mexican culture, colleagues reached out to thank me and learn more. Our strategy aims to weave diversity, inclusion, and belonging into the entire Alexion ecosystem, from employees to patients and the communities we serve. I have gained new friends and connections just by sharing who I am.”. Glassdoor. We understand that recruiting diverse talent and elevating voices is just the first step in our DI&B journey, and we do not stop there. They combine the collective power of internal experts, external advisors, and passionate employees to offer experiential DI&B learning, develop innovative ideas, and solve DI&B problems. From unconscious bias to managing uncertain times, WIL offers many events to help connect Alexion colleagues and provides a platform to have authentic conversations and discussions. View the full release here: https://www.businesswire.com/news/home/20200806005090/en/, “Establishing the Chief Diversity Officer role at Alexion is an important next step in our continued efforts to cultivate diversity, inclusion and a unique sense of belonging at the company, all of which enhances our ability to deliver on our mission of transforming the lives of patients with rare diseases and devastating conditions,” said Dr. Hantson. Alexion Pharmaceuticals has appointed Uzair Qadeer as the company’s first Chief Diversity Officer. “Now that I have been with Alexion for over a year, I’m still amazed by the organization’s commitment to diversity, inclusion, and belonging (DI&B).”, As a DI&B champion and advocate, Alcira has attended powerful colleague conversations focused on diversity and inclusion. Originally from Mexico, Alcira immigrated to the United States for college. To us, belonging is a pact to ensure that every person feels included because of their uniqueness, not despite it. Prior to joining Alexion in April 2017, Ms. Strellis served as Senior Vice President, Global Communications, Culture, and Diversity and Inclusion for Baxalta. In this new role, Mr. Qadeer will be responsible for shaping the company’s diversity, inclusion and belonging (DI&B) strategy, building relationships with key leaders, communities, and organizations to create awareness and advocacy for diversity and inclusion efforts, and advancing a unique culture of belonging for Alexion’s patients and employees. Our forward-thinking leadership team defines and drives a clear and progressive DI&B strategy. Qadeer serves as Alexion’s first chief diversity officer. 8,655 Diversity Inclusion jobs available in Remote on Indeed.com. About AlexionAlexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. YW Boston is the proud recipient of a grant from the Alexion Charitable Foundation to support our youth program the F.Y.R.E. View source version on businesswire.com: https://www.businesswire.com/news/home/20200806005090/en/, Alexion: Interview with Uzair Qadeer (Alexion), Stefanie Nickel (Sandoz), and Jennifer O’Lear (Merck kGaA) As Diversity, Inclusion, and Belonging (DI&B) become an increasingly important and recognised focus, we reflect on the progress being made within the pharmaceutical industry to improve both internally and externally for th Tristan's parents experienced a whirlwind of emotions and fear after learning their 5-year-old son had such a rare and serious disease. Despite having a constant struggle with symptoms, Roberta revisited her dreams and put herself through nursing school. VP, External Communications, Investors Alexion Pharmaceuticals, Inc. New Haven, CT 3 days ago Be among the first 25 applicants. Voluntary and primarily self-governed groups that aim to cultivate and sustain DI&B. The appointment of Mr. Qadeer will also accelerate Alexion’s efforts to embed DI&B across the company, spanning employee programs, corporate social responsibility initiatives, culture efforts, and patient programs. We remain dedicated to creating an environment where every person’s uniqueness is welcomed, celebrated, and amplified.”. This press release and further information about Alexion can be found at: www.alexion.com. Since then, she has discovered her passion of surrounding herself with a diverse set of friends and colleagues. Alexion Pharmaceuticals has appointed its first chief diversity officer, charged with cultivating “diversity, inclusion and a unique sense of belonging” at the company. “Those who interviewed me were genuinely interested in learning who I am as a person, what motivates me, and what uniqueness I bring to the table,” Alcira notes. Cultivating a culture of diversity, inclusion, and belonging is more than just a “check the box” exercise, it is integral to everything we do. ARGs are formed across various pillars, including gender, sexual orientation, ethnicity, national origin, and/or shared experience. degrees from Pennsylvania State University. Programs designed to ignite bold conversations, raise awareness, and achieve collective breakthroughs. Alexion aims to weave diversity, inclusion, and belonging into the company's entire ecosystem, from employees to patients and the communities we serve. Alexion has carved out a new position for chief diversity officer and filled it with an inside promotion.. Uzair Qadeer will now be responsible for their “diversity, inclusion and belonging” strategy, looking to reshape the biotech’s corporate culture. Everything was fine for about two weeks.”. However, he’s not content with simply adopting the best diversity, equality, and inclusion (DE&I) practices. © 2021 Alexion Pharmaceuticals, Inc. https://www.businesswire.com/news/home/20200806005090/en/. In this new role, Mr. Qadeer will be responsible for shaping the company’s diversity, inclusion and belonging (DI&B) strategy, building relationships with key leaders, communities, and organizations to … All Alexion colleagues have an opportunity to contribute in areas that are most meaningful to them. Mr. Qadeer will serve on Alexion’s Executive Committee, reporting to Ludwig Hantson, Ph.D., Chief Executive Officer at Alexion. If it is our DNA that makes each of us unique, it is our shared humanity that makes us all the same. The company, which has a large research presence in New Haven, announced it was elevating Uzair Qadeer to the new post on Aug. 6. This press release contains forward-looking statements, including statements related to: the Company’s planned implementation of the diversity, inclusion and belonging (DI&B) strategy; the expected benefits of the DI&B strategy and its implementation; the acceleration of Alexion’s efforts to embed DI&B across the organizational ecosystem, spanning employee programs, corporate social responsibility initiatives, culture efforts, and patient programs; the Company will continue efforts to cultivate diversity, inclusion and a unique sense of belonging at the Company, all of which enhances our ability to deliver on our mission of transforming the lives of patients with rare diseases and devastating conditions; and the Chief Diversity Officer will help build a stronger, even more inclusive organization. Partnerships “At Alexion, we believe that diversity is having a seat at the table, inclusion is having a voice, and belonging is having that voice be heard. Read employee reviews and ratings on Glassdoor to decide if Alexion Pharmaceuticals is right for you. About Us; In this role, Ms. Strellis created and executed a culture transformation vision, diversity and inclusion strategy, and a … Additionally, Mr. Qadeer also taught at Rutgers, The State University of New Jersey. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).
Pandas Drop Columns With Nan, Wohnung Mit Garten In Beckum Kaufen, Darja Alexandrowna Schukowa Aaron Alexander Abramovich, Elebrato Ellipta 92/55/22 Wirkstoff, Alexander Der Große Film Stream,
Neue Kommentare